nach oben

Current Pain and Headache Reports

Erschienen in:

01.04.2018 | Episodic Migraine (S Nahas, Section Editor)

The Role of Endothelin in the Pathophysiology of Migraine—a Systematic Review

verfasst von: Afrim Iljazi, Cenk Ayata, Messoud Ashina, Anders Hougaard

Erschienen in: Current Pain and Headache Reports | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Vasoactive peptides play a key role in the attack-initiating cascade of migraine. Recent studies have highlighted a potentially important role for endothelin-1, a potent vasoconstrictor peptide, in migraine pathophysiology. Here, we review the current data on endothelin’s involvement in migraine.

Recent Findings

We identified 23 articles. Nine studies reported on endothelin-1 plasma concentrations in patients with migraine, eight studies investigated relevant genetic associations, five studies investigated endothelin-1 and spreading depression in animals, and one randomized controlled clinical trial tested the efficacy of an endothelin antagonist in the acute treatment of migraine in patients both with and without aura. Elevated endothelin-1 plasma levels have been reported in the early phase of migraine attacks. Genetic abnormalities related to the endothelin type A receptor have been reported in migraineurs. Endothelin-1 potently induces spreading depression in animals, which may explain the connection between endothelial irritation and migraine aura.

Summary

Endothelin-1 could be a primary factor in the attack-triggering cascade of migraine attacks with and without aura. Additional studies in humans and animal models are needed to further elucidate the role of endothelin-1 in migraine.

Ashina M, Hansen JM, á Dunga BO, Olesen J. Human models of migraine—short-term pain for long-term gain. Nat Rev Neurol. 2017;13:713–24. https://doi.org/10.1038/nrneurol.2017.137.CrossRefPubMed

Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179–86.CrossRefPubMed

Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia. 1999;19:660–7.CrossRefPubMed

Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98:4687–92.CrossRefPubMedPubMedCentral

Ayata C. Cortical spreading depression triggers migraine attack: pro. Headache. 2010;50:725–30.CrossRefPubMed

Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002;8:136–42.CrossRefPubMed

Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol. 2011;69:855–65.CrossRefPubMedPubMedCentral

Nozari A, Dilekoz E, Sukhotinsky I, et al. Microemboli may link spreading depression, migraine aura and patent foramen ovale. Ann Neurol. 2010;67:221–9.CrossRefPubMedPubMedCentral

Stam AH, Haan J, Van Den Maagdenberg AMJM, Ferrari MD, Terwindt GM. Migraine and genetic and acquired vasculopathies. Cephalalgia. 2009;29:1006–17.CrossRefPubMed

10.

Lauritzen M, Skyhøj Olsen T, Lassen NA, Paulson OB. Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol. 1983;13:633–41.CrossRefPubMed

11.

Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol. 1981;9:344–52.CrossRefPubMed

12.

• Dreier JP, Kleeberg J, Petzold G, Priller J, Windmüller O, Orzechowski H-D, et al. Endothelin-1 potently induces Leão’s cortical spreading depression in vivo in the rat: a model for an endothelial trigger of migrainous aura? Brain. 2002;125:102–12. First report of ET-1 eliciting CSD in an animal model.CrossRefPubMed

13.

karim KA, Rockey DC. Endothelin-biology and disease. Cell Signal. 2010;22:1615–25.CrossRef

14.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–5.CrossRefPubMed

15.

• Kallela M, Färkkilä M, Saijonmaa O, Fyhrquist F. Endothelin in migraine patients. Cephalalgia. 1998;18:329–32. Reports of markedly elevated ET-1 levels during migraine headache compared to headache-free period and to healthy controls.CrossRefPubMed

16.

• Färkkilä M, Palo J, Saijonmaa O, Fyhrquist F. Raised plasma endothelin during acute migraine attack. Cephalalgia. 1992;12:383–4. Reports of markedly elevated ET-1 levels during migraine headache compared to healthy controls.CrossRefPubMed

17.

Bianchi A, Pitari G, Amenta V, Giuliano F, Gallina M, Costa R, et al. Endothelial, haemostatic and haemorheological modifications in migraineurs. Artery. 1996;22:93–100.PubMed

18.

Eftedal OS, Lydersen S, Helde G, White L, Brubakk AO, Stovner LJ. A randomized, double blind study of the prophylactic effect of hyperbaric oxygen therapy on migraine. Cephalalgia. 2004;24:639–44.CrossRefPubMed

19.

Hamed SA, Hamed EA, Ezz Eldin AM, Mahmoud NM. Vascular risk factors, endothelial function, and carotid thickness in patients with migraine: relationship to atherosclerosis. J Stroke Cerebrovasc Dis. 2010;19:92–103.CrossRefPubMed

20.

Hasselblatt M, Kohler J, Volles E, Ehrenreich H. Simultaneous monitoring of endothelin-1 and vasopressin plasma levels in migraine. Neuroreport. 1999;10:423–5.CrossRefPubMed

21.

Nattero G, Mengozzi G, Inconis T, Paradisi L. Nitric oxide, endothelin-1, and transcranial Doppler in migraine. Findings in interictal conditions and during migraine attack. Headache. 1996;36:307–11.CrossRefPubMed

22.

Gallai V, Sarchielli P, Firenze C, Trequattrini A, Paciaroni M, Usai F, et al. Endothelin 1 in migraine and tension-type headache. Acta Neurol Scand. 1994;89:47–55.CrossRefPubMed

23.

May A, Gijsman HJ, Wallnöfer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain. 1996;67:375–8.CrossRefPubMed

24.

• Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser M-G, Alperovitch A. Association between migraine and endothelin type A receptor (ETA -231 A/G) gene polymorphism. Neurology. 2001;56:1273–7. First GWAS reporting an association between EDNRA and migraine.CrossRefPubMed

25.

Lemos C, Neto JL, Pereira-Monteiro J, Mendonça D, Barros J, Sequeiros J, et al. A role for endothelin receptor type A in migraine without aura susceptibility? A study in Portuguese patients. Eur J Neurol. 2011;18:649–55.CrossRefPubMed

26.

Joshi G, Pradhan S, Mittal B. Vascular gene polymorphisms (EDNRA −231 G>A and APOE HhaI) and risk for migraine. DNA Cell Biol. 2011;30:577–84.CrossRefPubMed

27.

Tikka-Kleemola P, Kaunisto M, Hämäläinen E, et al. Genetic association study of Endothelin-1 and its receptors EDNRA and EDNRB in migraine with aura: BRIEF REPORT. Cephalalgia. 2009;29:1224–31.CrossRefPubMedPubMedCentral

28.

Louter MA, Fernandez-Morales J, de Vries B, et al. Candidate-gene association study searching for genetic factors involved in migraine chronification. Cephalalgia. 2015;35:500–7.CrossRefPubMed

29.

Lisi V, Garbo G, Battistella P, Miccichè F, Stecca A, Terrazzino S, et al. Endothelin receptor A −231 G>A polymorphism: no linkage to primary pediatric headache. Headache. 2006;46:486–91.CrossRefPubMed

30.

MacClellan LR, Howard TD, Cole JW, Stine OC, Giles WH, O’Connell JR, et al. Relation of candidate genes that encode for endothelial function to migraine and stroke: the stroke prevention in young women study. Stroke. 2009;40:550–7.CrossRef

31.

•• Gupta RM, Hadaya J, Trehan A, et al. A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression. Cell. 2017;170:522–533.e15. Major GWAS, genetic fine mapping and CRISPR-study, showing a link between a common snip of the EDN-1 gene and migraine.CrossRefPubMedPubMedCentral

32.

Goadsby PJ, Adner M, Edvinsson L. Characterization of endothelin receptors in the cerebral vasculature and their lack of effect on spreading depression. J Cereb Blood Flow Metab. 1996;16:698–704.CrossRefPubMed

33.

Petzold GC, Einhäupl KM, Dirnagl U, Dreier JP. Ischemia triggered by spreading neuronal activation is induced by endothelin-1 and hemoglobin in the subarachnoid space. Ann Neurol. 2003;54:591–8.CrossRefPubMed

34.

Kleeberg J, Petzold GC, Major S, Dirnagl U, Dreier JP. ET-1 induces cortical spreading depression via activation of the ETA receptor/phospholipase C pathway in vivo. Am J Physiol Heart Circ Physiol. 2004;286:H1339–46.CrossRefPubMed

35.

Dreier JP, Kleeberg J, Alam M, Major S, Kohl-Bareis M, Petzold GC, et al. Endothelin-1-induced spreading depression in rats is associated with a microarea of selective neuronal necrosis. Exp Biol Med (Maywood). 2007;232:204–13.

36.

Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacol Rev. 2016;68:357–418.CrossRefPubMedPubMedCentral

37.

Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 1999;61:391–415.CrossRefPubMed

38.

Russell F, Davenport A. Secretory pathways in endothelin synthesis. Br J Pharmacol. 1999;126:391–8.CrossRefPubMedPubMedCentral

39.

Arngrim N, Schytz HW, Britze J, et al. Migraine induced by hypoxia: an MRI spectroscopy and angiography study. Brain. 2016;139:723–37.CrossRefPubMed

40.

Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest. 1991;88:1054–7.CrossRefPubMedPubMedCentral

41.

Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464–9.CrossRefPubMed

42.

Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, Noe E, et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res. 1997;33:196–200.CrossRefPubMed

43.

Simonneau G, Galiè N, Jansa P, Meyer GMB, Al-Hiti H, Kusic-Pajic A, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014;172:332–9.CrossRefPubMed

44.

Juvela S. Plasma endothelin and big endothelin concentrations and serum endothelin-converting enzyme activity following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;97:1287–93.CrossRefPubMed

45.

Kessler IM, Pacheco YG, Lozzi SP, de Araújo AS, Onishi FJ, de Mello PA. Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2005;64 Suppl 1:S1:2-5; discussion S1:5.

46.

Bellapart J, Jones L, Bandeshe H, Boots R. Plasma endothelin-1 as screening marker for cerebral vasospasm after subarachnoid hemorrhage. Neurocrit Care. 2014;20:77–83.CrossRefPubMed

47.

Kästner S, Oertel MF, Scharbrodt W, Krause M, Böker DK, Deinsberger W. Endothelin-1 in plasma, cisternal CSF and microdialysate following aneurysmal SAH. Acta Neurochir. 2005;147:1271–9.CrossRefPubMed

48.

Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension. 1990;15:493–6.CrossRefPubMed

49.

Cecioni I, Modesti PA, Poggesi L, Rocchi F, Rega L, Serneri GGN. Endothelin-1 urinary excretion, but not endothelin-1 plasma concentration, is increased in renovascular hypertension. J Lab Clin Med. 1999;134:386–91.CrossRefPubMed

50.

Žeravica R, Čabarkapa V, Ilinčić B, Sakač V, Mijović R, Nikolić S, et al. Plasma endothelin-1 level, measured glomerular filtration rate and effective renal plasma flow in diabetic nephropathy. Ren Fail. 2015;37:681–6.CrossRefPubMed

51.

Alam I, Bass NM, Bacchetti P, Gee L, Rockey DC. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol. 2000;95:199–203.CrossRefPubMed

52.

Martinet JP, Legault L, Cernacek P, Louise R, Dufresne MP, Spahr L, et al. Changes in plasma endothelin-1 and big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites. J Hepatol. 1996;25:700–6.CrossRefPubMed

53.

Nozue T, Kobayashi A, Uemasu F, Takagi Y, Endoh H, Sako A. Plasma endothelin-1 levels of children with cirrhosis. J Pediatr Gastroenterol Nutr. 1995;21:220–3.CrossRefPubMed

54.

Chongsrisawat V, Chatchatee P, Samransamruajkit R, Vanapongtipagorn P, Chottivittayatarakorn P, Poovorawan Y. Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension. Pediatr Surg Int. 2003;19:478–81.CrossRefPubMed

55.

Tsai YT, Lin HC, Yang MCM, Lee FY, Hou MC, Chen LS, et al. Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function. J Hepatol. 1995;23:681–8.CrossRefPubMed

56.

Lindblad M, Hougaard A, Amin FM, Ashina M. Can migraine aura be provoked experimentally? A systematic review of potential methods for the provocation of migraine aura. Cephalalgia. 2016;1–15.

57.

Janzen R, Tänzer A, Zschocke S, Dieckmann H. Postangiographische Spätreaktione der Hirngefässe bei Migräne-Kranken. Z Neurol. 1972;201:24–42.PubMed

58.

Beekman R, Nijssen PCG, van Rooij WJ, Wijnalda D. Migraine with aura after intracranial endovascular procedures. Headache. 2001;41:410–3.CrossRefPubMed

59.

Koyama S, Kawamura M. Persistent visual aura following catheter ablation in a patient with WPW syndrome. Behav Neurol. 2007;18:187–92.CrossRefPubMedPubMedCentral

60.

Staals JE, Braun KP, van Loo-Maurus KE, Vles JS. Stenting for coarctation of the aorta precipitating migraine with aura. J Child Neurol. 2007;22:321–3.CrossRefPubMed

61.

Gillet JL, Donnet A, Lausecker M, Guedes JM, Guex JJ, Lehmann P. Pathophysiology of visual disturbances occurring after foam sclerotherapy. Phlebology. 2010;25:261–6.CrossRefPubMed

62.

Frullini A, Barsotti MC, Santoni T, Duranti E, Burchielli S, Di SR. Significant endothelin release in patients treated with foam sclerotherapy. Dermatol Surg. 2012;38:741–7.CrossRefPubMed

63.

Frullini A, Felice F, Burchielli S, Di Stefano R. High production of endothelin after foam sclerotherapy: a new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy. Phlebol J Venous Dis. 2011;26:203–8.CrossRef

64.

Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJH, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 2013;12:454–61.CrossRefPubMed

65.

Zheng S, Wu Y, Jiao J, Wei L, Xu M, Lian J, et al. Clinical efficacy of Chifeng Yingyuan manipulation for migraine and its effects on endothelin and nitric oxide. World J Acupunct - Moxibustion. 2013;23:46–9.CrossRef

66.

Parker JD, Thiessen JJ, Reilly R, Tong JH, Stewart DJ, Pandey AS. Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J Pharmacol Exp Ther. 1999;289:261–5.PubMed

67.

Johnström P, Fryer TD, Richards HK, Harris NG, Barret O, Clark JC, et al. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ETB receptors in vivo. Br J Pharmacol. 2009;144:115–22.CrossRef

68.

Hougaard A, Amin FM, Christensen CE, Younis S, Wolfram F, Cramer SP, Larsson HBW, Ashina M. Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 2017;1–10.

69.

Ayata C, Lauritzen M. Spreading depression, spreading depolarizations, and the cerebral vasculature. Physiol Rev. 2015;95:953–93.CrossRefPubMedPubMedCentral

70.

Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA, Andersen AR, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol. 1990;28:791–8.CrossRefPubMed

71.

Dohmen C, Sakowitz OW, Fabricius M, et al. Spreading depolarizations occur in human ischemic stroke with high incidence. Ann Neurol. 2008;63:720–8.CrossRefPubMed

72.

Olesen J. The international classification of headache disorders, 3rd edition. Cephalagia. 2013;33:629–808.CrossRef

73.

Gaist D, Garde E, Blaabjerg M, et al. Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study. Brain. 2016;139:2015–23.CrossRefPubMedPubMedCentral

74.

Peng K-P, Chen Y-T, Fuh J-L, Tang C-H, Wang S-J. Migraine and incidence of ischemic stroke: a nationwide population-based study. Cephalalgia 2016;1–9.

75.

Smith TP, Haymond T, Smith SN, Sweitzer SM. Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. J Pain Res. 2014;7:531–45.CrossRefPubMedPubMedCentral

76.

Wang Y, Wang DH. Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP. Am J Physiol Heart Circ Physiol. 2004;287:H1868–74.CrossRefPubMed

77.

Miura K, Yukimura T, Yamashita Y, Shimmen T, Okumura M, Imanishi M, et al. Endothelin stimulates the renal production of prostaglandin E2 and I2 in anesthetized dogs. Eur J Pharmacol. 1989;170:91–3.CrossRefPubMed

78.

Bourque SL, Davidge ST, Adams MA. The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol. 2011;300:R1288–95.CrossRefPubMed

79.

Schytz HW, Schoonman GG, Ashina M. What have we learnt from triggering migraine? Curr Opin Neurol. 2010;23:259–65.CrossRefPubMed

80.

Garlichs CD, Zhang H, Mügge A, Daniel WG. Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells. Eur J Clin Investig. 1999;29:12–6.CrossRef

81.

Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediat Inflamm. 2008;2008:1–7.CrossRef

82.

Ghiadoni L, Virdis A, Magagna A, Taddei S. Effect of the angiotensin II type 1 receptor blocker essential hypertension. Online. 2000;501–506.

83.

Joseph EK, Levine JD. Role of endothelial cells in antihyperalgesia induced by a triptan and β-blocker. Neuroscience. 2013;232:83–9.CrossRefPubMed

Titel: The Role of Endothelin in the Pathophysiology of Migraine—a Systematic Review
verfasst von: Afrim Iljazi
Cenk Ayata
Messoud Ashina
Anders Hougaard
Publikationsdatum: 01.04.2018
Verlag: Springer US
Erschienen in: Current Pain and Headache Reports / Ausgabe 4/2018
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-018-0682-8

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

The Role of Endothelin in the Pathophysiology of Migraine—a Systematic Review

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Cerebral Hyperperfusion Syndrome After Carotid Revascularization and Acute Ischemic Stroke

Treatment of the Patient with Refractory Headache

Novel Interventional Nonopioid Therapies in Headache Management

Cyclic Vomiting Syndrome in Children

Spinal Cord Stimulation, MILD Procedure, and Regenerative Medicine, Novel Interventional Nonopioid Therapies in Chronic Pain

A Review of Current Treatment Options for Coccygodynia

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS